Nektar Therapeutics | NKTR - Sales Revenues


Nektar Therapeutics reported $10.86M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
Baxter International USD 2.96B 260M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.74B 490M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 71.19B 5.78B Jun/2026
Dr.Reddys Laboratories INR 80.71B 5.25B Jun/2026
Eisai JPY 234.33B 28.9B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Exelixis USD 628.69M 17.89M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.6B 310M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026